IRLAB Therapeutics AB
STO:IRLAB A

Watchlist Manager
IRLAB Therapeutics AB Logo
IRLAB Therapeutics AB
STO:IRLAB A
Watchlist
Price: 12.6 SEK -1.95% Market Closed
Market Cap: 652.5m SEK
Have any thoughts about
IRLAB Therapeutics AB?
Write Note

IRLAB Therapeutics AB
Net Income (Common)

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

IRLAB Therapeutics AB
Net Income (Common) Peer Comparison

Comparables:
CALTX
CAMX
S
SECARE
MOB
I
FLERIE

Competitive Net Income (Common) Analysis
Latest Figures & CAGR of Competitors

Company Net Income (Common) CAGR 3Y CAGR 5Y CAGR 10Y
IRLAB Therapeutics AB
STO:IRLAB A
Net Income (Common)
-kr177.8m
CAGR 3-Years
-25%
CAGR 5-Years
-19%
CAGR 10-Years
N/A
Calliditas Therapeutics AB
STO:CALTX
Net Income (Common)
-kr480.4m
CAGR 3-Years
7%
CAGR 5-Years
-69%
CAGR 10-Years
N/A
Camurus AB
STO:CAMX
Net Income (Common)
kr223.3m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
S
Swedencare AB (publ)
STO:SECARE
Net Income (Common)
kr76.2m
CAGR 3-Years
20%
CAGR 5-Years
22%
CAGR 10-Years
N/A
Moberg Pharma AB (publ)
STO:MOB
Net Income (Common)
-kr21.1m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
I
InDex Pharmaceuticals Holding AB
STO:FLERIE
Net Income (Common)
-kr190.4m
CAGR 3-Years
-40%
CAGR 5-Years
-21%
CAGR 10-Years
N/A

See Also

What is IRLAB Therapeutics AB's Net Income (Common)?
Net Income (Common)
-177.8m SEK

Based on the financial report for Dec 31, 2023, IRLAB Therapeutics AB's Net Income (Common) amounts to -177.8m SEK.

What is IRLAB Therapeutics AB's Net Income (Common) growth rate?
Net Income (Common) CAGR 5Y
-19%

Over the last year, the Net Income (Common) growth was -57%. The average annual Net Income (Common) growth rates for IRLAB Therapeutics AB have been -25% over the past three years , -19% over the past five years .

Back to Top